• Explore /
  • Poster
  • / The survival outcome, prostate-specific antigen (PSA) response and risk of fatigue of enzalutamide as first- and later-line treatment options in patients with metastatic castration-resistant prostate cancer (mCRPC): The real-world experience.

The survival outcome, prostate-specific antigen (PSA) response and risk of fatigue of enzalutamide as first- and later-line treatment options in patients with metastatic castration-resistant prostate cancer (mCRPC): The real-world experience.

Abstract Poster

Authors

null

Darren M.C. Poon

State Key Laboratory in Oncology in South China, Sir YK Pao Centre for Cancer, Hong Kong Cancer Institute and Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong

Darren M.C. Poon , Kenneth C.W. Wong , T.W. Chan , Kitty Law , Kuen Chan , Ka Chai Lee , Conrad Lee , Chan Fong Ting

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, and Testicular Cancers

Track

Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Prostate Cancer - Advanced Disease

Citation

J Clin Oncol 36, 2018 (suppl 6S; abstr 330)

DOI

10.1200/JCO.2018.36.6_suppl.330

Abstract #

330

Poster Bd #

C21

Abstract Disclosures

Similar Posters

First Author: Orazio Caffo

First Author: Orazio Caffo

First Author: Antoine Angelergues

First Author: Esmail M. Al-Ezzi